secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001682852-23-000030
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna and Immatics announce $120M upfront oncology collaboration for TCR bispecifics and cancer vaccines
--------------------------------------------------------------------------------

- Immatics receives $120M upfront plus research funding; milestones could exceed $1.7B plus tiered royalties on net sales.
- Collaboration spans three pillars: mRNA-expressed TCER bispecifics, novel mRNA cancer vaccines using XPRESIDENT, and IMA203 TCR-T combo with Moderna's PRAME vaccine.
- Moderna leads clinical development and commercialization of TCER and vaccine products; Immatics handles preclinical/Phase 1 for the combo study.
- Immatics holds option to enter global profit/loss share for the most advanced TCER program.
- Deal subject to customary US antitrust clearance; Moderna retains full ownership of its PRAME compound.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000030/0001682852-23-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000030/mrna-20230911.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer